Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary SyndromePrimary Results of the DISPERSE-2 Trial
Christopher P. Cannon, MD, FACC*,*,
Steen Husted, MD ,1,
Robert A. Harrington, MD, FACC ,2,
Benjamin M. Scirica, MD*,
Håkan Emanuelsson, MD, PhD ,3,
Gary Peters, MD||,4,
Robert F. Storey, MD¶,5 for the DISPERSE-2 Investigators
* TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
Århus University Hospital, Århus, Denmark
Duke Clinical Research Institute, Durham, North Carolina
AstraZeneca, Mölndal, Sweden
|| AstraZeneca, Wilmington, Delaware
¶ University of Sheffield, Sheffield, United Kingdom.
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Rates of Major or Minor Bleeding Through 4 Weeks
Rates of bleeding at week 4 (primary end point, A) and overall in the trial (B). The percentages given at the top of the bar graphs are the rates of total bleeding, defined as major or minor. *Minor bleeding without major bleeding. bid = twice a day; qd = once a day.
|
|
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Rates of Major or Minor Bleeding Within 48 h of Randomization
The percentages given at the top of the bar graphs are the rates of total bleeding, defined as major or minor. *Minor bleeding without major bleeding; loading dose. Abbreviations as in Figure 1.
|
|
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Kaplan-Meier Estimates of Clinical End Points
Cumulative risk of (A) composite clinical end point (cardiovascular death, myocardial infarction, or stroke), and (B) myocardial infarction events. bid = twice a day.
|
|
|
